CorMedix CRMD took a major step to diversify its revenue base and lessen reliance on its lead marketed product, DefenCath ...

Pfizer remains a compelling bargain, supported by a strong dividend yield and undervalued financial metrics, despite post-pandemic headwinds. PFE's acquisition of Metsera positions it for growth in ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Deal marks Pfizer's re-entry into obesity treatment market Pfizer shares rise 1.4%, Novo Nordisk falls 1.3% Metsera candidate MET-097i advances to late-stage trials The greenlight from Metsera's ...

Pfizer (PFE) CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Investconference that the $10 billion acquisition of GLP-1 maker Metsera (MTSR ...

After a chaotic and fierce bidding clash that only burst out into public view a little more than a week ago, Pfizer has prevailed in its pursuit of obesity biotech Metsera. The companies agreed to an ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy. By Francesca Regalado The obesity drug developer ...

Pfizer's Q3 earnings fell, but the company still raised its full-year earnings guidance. Major cost reductions remain on track, which should significantly boost the drugmaker's bottom line. Pfizer's ...

Heated bidding war continues between Pfizer, Novo Nordisk for obesity biotech firm Pfizer's lawyer claims Novo's offer is illegal, poses regulatory risks Novo defends deal structure, engages in ...

Pfizer has axed 11 programs including two pipeline assets from its $43 billion Seagen acquisition, work on a BioNTech-partnered mRNA vaccine and a midstage metabolic dysfunction-associated ...

CorMedix CRMD is expected to report its third-quarter 2025 earnings results soon. The Zacks Consensus Estimate for sales and earnings is pegged at $70 million and 48 cents per share, respectively.